A non-viral gene editing platform for cell therapies and translational autoimmune disease modeling

用于细胞治疗和转化自身免疫性疾病建模的非病毒基因编辑平台

基本信息

项目摘要

SUMMARY Gene edited T lymphocytes hold promise as safe and effective living therapies for a wide range of human diseases, including autoimmune disease. However, viral methods currently employed to engineer cells for therapy are imprecise, exorbitantly expensive, and have high failure rates. These drawbacks limit development of cell therapies and prevent them from penetrating alternative markets, where natural, spontaneous disease can be addressed in pre-IND and IND-enabling studies to improve therapeutic outcomes. This proposal is focused on optimizing and advancing the development of a novel, non-viral method for highly efficient and precise engineering of human T cells. The innovation is a nanoplasmid-based, site-specific gene editing platform that enables tunable manufacturing of human cell therapeutics. Not only will this precise gene editing platform yield a quantum leap forward in cellular engineering, but the resultant product will also provide sustained clinical improvements over the standard of care for B cell–mediated autoimmune diseases, for which no current cell therapies exist. This Phase I proposal is focused on optimizing the efficiency of the GeneWeld site-specific gene editing platform and demonstrating the in vitro functionality of using GeneWeld to reprogram human Chimeric Antigen Receptor (CAR)-T cells for elimination of a targeted B cell population.
总结 基因编辑的T淋巴细胞有望成为广泛人类的安全有效的活体疗法。 疾病,包括自身免疫性疾病。然而,目前用于工程化细胞的病毒方法, 治疗是不精确的,过于昂贵,并具有高失败率。这些弊端限制了发展 并阻止它们渗透替代市场,在这些市场中,自然的,自发的疾病 可以在IND前和IND使能研究中解决,以改善治疗结局。 该提案的重点是优化和推进一种新型的非病毒方法的开发, 高效精确地改造人类T细胞。这项创新是一种基于纳米质粒的位点特异性基因 编辑平台,使人类细胞治疗的可调制造。这个精确的基因不仅 编辑平台在细胞工程方面产生了巨大的飞跃,但由此产生的产品也将提供 持续的临床改善超过B细胞介导的自身免疫性疾病的护理标准, 目前还不存在细胞疗法。第一阶段的提案重点是优化GeneWeld的效率 位点特异性基因编辑平台,并证明使用GeneWeld重编程的体外功能 人嵌合抗原受体(CAR)-T细胞用于消除靶向B细胞群。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wesley Wierson其他文献

Wesley Wierson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 33.74万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 33.74万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 33.74万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 33.74万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 33.74万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 33.74万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了